Detailed price information for Cardiol Therapeutics (CRDL-Q) from The Globe and Mail including charting and trades.
Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.
Cardiol Therapeutics is a binary, catalyst-driven biotech, with its investment case hinging on CardiolRx’s Phase III MAVERIC trial. See more on CRDL stock here.
Detailed price information for Cardiol Therapeutics (CRDL-Q) from The Globe and Mail including charting and trades.
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada, together with a corresponding registration statement on Form F-10 (the "Registration Statement") with the
Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.
Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.
Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
This is the newest page. Registered accounts read further back.